Cardiovascular Diseases Modeling and Assay Services

Aging of the population and better survival of patients affected by coronary heart disease have led to an increasing number of patients with chronic heart failure, the common end stage of virtually all cardiac diseases. In addition, heart failure is a frequent complication of other cardiac disorders, such as cardiac hypertrophy, myocardial infarction and arrhythmia.

The knowledge of the mechanisms and drug response are essential for the development and assessment of new chemical entities for different kinds of cardiovascular diseases. Current drug therapies alleviate symptoms for only 50 to 70% of cardiovascular disease patients and often with unwanted side effects. Cardiotoxicity remains a major concern during drug development, with increased proarrhythmic potential being the main culprit. The pharmaceutical industry is challenged by the growing cost of research and development, and cannot afford drug attrition in late phases of development or withdrawals of approved drugs. Thus, there is an urgent need for extensive research effort and better treatment options to develop novel therapeutic strategies for cardiovascular diseases.

The conventional models for cardiovascular diseases are often built with Rat, rabbit and canine. However, human cardiomyocytes differ significantly from those of other species. The rodent and canine hearts have obvious difference in electrophysiological properties and heart beats compared to human hearts. Human stem and induced pluripotent stem (iPS) cells based cell models are able to avoid such disadvantages and are more physiological surrogate of the ‘native’ cellular context. And it is a replacement of ethically critical animal experiments. Moreover, it is relatively stable over days or weeks compared to primary cells. This information highlights the importance and the preferred source of using human stem and iPS cells as both disease models and tools for drug screening.

With over 10 years’ experiences in the field of human stem and iPS cells, Creative Bioarray is offering cardiovascular diseases modeling and assay services based on human stem and iPS cells to help our customer opening the door for generating new mechanistic insight into cardiovascular disease pathophysiology and improving the process of drug development.